HealthDay 
(8/21, Mann) reports, "People with psoriasis who take a new class of
drugs known as tumor necrosis factor (TNF) inhibitors may be at a lower
risk for heart attack than their counterparts who only use topical
medications to treat this inflammatory skin condition," according to a study published online Aug. 20 in the Archives of Dermatology.
(8/21, Mann) reports, "People with psoriasis who take a new class of
drugs known as tumor necrosis factor (TNF) inhibitors may be at a lower
risk for heart attack than their counterparts who only use topical
medications to treat this inflammatory skin condition," according to a study published online Aug. 20 in the Archives of Dermatology.
WebMD
(8/21, Doheny) points out, "Those on oral medicines such as
cyclosporine, methotrexate, Soriatane [acitretin], or given light
therapy had nearly the same reduction in risk, compared to those on
skin-based -- or topical -- medicines," the study found. Researchers
arrived at this conclusion after following about 9,000 patients for
approximately four years. Participants "in the TNF inhibitor group had a
50% reduction in heart attack, compared to the topical agent group,"
while those taking oral medicines or receiving phototherapy had a
46% reduction in heart-attack risk.
(8/21, Doheny) points out, "Those on oral medicines such as
cyclosporine, methotrexate, Soriatane [acitretin], or given light
therapy had nearly the same reduction in risk, compared to those on
skin-based -- or topical -- medicines," the study found. Researchers
arrived at this conclusion after following about 9,000 patients for
approximately four years. Participants "in the TNF inhibitor group had a
50% reduction in heart attack, compared to the topical agent group,"
while those taking oral medicines or receiving phototherapy had a
46% reduction in heart-attack risk.
MedPage Today
(8/21, Phend) quotes the study authors, who concluded, "It seems that
controlling psoriasis with aggressive therapy and, thus, lowering
inflammation leads to a reduction in MI risk." MedPage Today explained,
"As a systemic inflammatory disease, psoriasis is linked to many
cardiovascular risks, from obesity and atherosclerosis to type 2
diabetes, stroke, MI, and cardiac death." However, "the study didn't
compare the individual TNF blockers -- infliximab (Remicade), etanercept
(Enbrel), and adalimumab (Humira) -- used in
psoriasis." Reuters (8/21, Pittman) also covers the story.
(8/21, Phend) quotes the study authors, who concluded, "It seems that
controlling psoriasis with aggressive therapy and, thus, lowering
inflammation leads to a reduction in MI risk." MedPage Today explained,
"As a systemic inflammatory disease, psoriasis is linked to many
cardiovascular risks, from obesity and atherosclerosis to type 2
diabetes, stroke, MI, and cardiac death." However, "the study didn't
compare the individual TNF blockers -- infliximab (Remicade), etanercept
(Enbrel), and adalimumab (Humira) -- used in
psoriasis." Reuters (8/21, Pittman) also covers the story.
No comments:
Post a Comment